{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:47:58Z","timestamp":1795034878958,"version":"4.10.2"},"reference-count":36,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,15]]},"abstract":"<jats:p>A multicenter retrospective analysis was performed to estimate the frequency of thrombosis and hemorrhage after surgical procedures in patients with polycythemia vera (PV) and patients with essential thrombocythemia (ET). Data from 105 patients with PV and 150 patients with ET were analyzed, for a total of 311 surgical interventions. An emergency procedure was performed in 25 (8.1%) patients; 194 surgeries were done under general anesthesia, and 21 (23%) of 91 abdominal interventions were done under laparoscopy; 155 (50.1%) were major surgeries. Subcutaneous heparin was administered in 169 (54.3%) of 311 cases and antiplatelet therapy in 48 (15.4%) of 311 case interventions. One hundred eighty-eight (74%) of 255 patients were on cytoreductive therapy before surgery. No events were observed in 259 (83.2%) of 311 procedures during 3 months of follow-up; there were 12 arterial and 12 venous thrombotic events, 23 major and 7 minor hemorrhages, and 5 deaths. Arterial thromboses were more frequent in ET (5.3% vs 1.5%; P = .08), venous events were more frequent in PV (7.7% vs 1.1%; P = .002). There was not a correlation between bleeding episodes and the type of diagnosis, use of antithrombotic prophylaxis, or type of surgery. A high proportion of PV and ET surgeries was complicated by vascular occlusion (7.7%) or by a major hemorrhage (7.3%). Prospective investigations analyzing the optimal prophylaxis in these patients are suggested.<\/jats:p>","DOI":"10.1182\/blood-2007-07-102665","type":"journal-article","created":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T20:40:04Z","timestamp":1191271204000},"page":"666-671","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":102,"title":["Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey"],"prefix":"10.1182","volume":"111","author":[{"given":"Marco","family":"Ruggeri","sequence":"first","affiliation":[{"name":"Department of Hematology, San Bortolo Hospital, Vicenza;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rodeghiero","sequence":"additional","affiliation":[{"name":"Department of Hematology, San Bortolo Hospital, Vicenza;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Tosetto","sequence":"additional","affiliation":[{"name":"Department of Hematology, San Bortolo Hospital, Vicenza;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[{"name":"Department of Hematology, San Bortolo Hospital, Vicenza;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Scognamiglio","sequence":"additional","affiliation":[{"name":"Department of Hematology, San Bortolo Hospital, Vicenza;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Finazzi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Delaini","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Mic\u00f2","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Florence, Florence;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Antonioli","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Florence, Florence;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Catholic University, Rome;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Za","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Catholic University, Rome;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gugliotta","sequence":"additional","affiliation":[{"name":"Service of Hematology, Santa Maria Nuova Hospital, Reggio Emilia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Tieghi","sequence":"additional","affiliation":[{"name":"Service of Hematology, Santa Maria Nuova Hospital, Reggio Emilia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Mazzucconi","sequence":"additional","affiliation":[{"name":"Department of Biocellular Technology and Hematology, La Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Biocellular Technology and Hematology, La Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111813141526200_B1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes.","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"2019111813141526200_B2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"key":"2019111813141526200_B3","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C","article-title":"Life expectancy of patients with chronic nonleukemic myeloproliferative disorders.","volume":"67","author":"Rozman","year":"1991","journal-title":"Cancer"},{"key":"2019111813141526200_B4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long term complications rates, and prognostic factors.","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"2019111813141526200_B5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia.","volume":"123","author":"Gruppo Italiano Studio Policitemia","year":"1995","journal-title":"Ann Inter Med"},{"key":"2019111813141526200_B6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"key":"2019111813141526200_B7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythemia vera and essential thrombocythemia.","volume":"128","author":"Elliott","year":"2004","journal-title":"Br J Haematol"},{"key":"2019111813141526200_B8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2141.2005.05543.x","article-title":"Essential thrombocytemia: challenges and evidence-based management.","volume":"130","author":"Harrison","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111813141526200_B9","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single institution experience with 223 patients.","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"2019111813141526200_B10","first-page":"1180","article-title":"Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.","volume":"87","author":"Randi","year":"2002","journal-title":"Haematologica"},{"key":"2019111813141526200_B11","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica"},{"key":"2019111813141526200_B12","first-page":"339","article-title":"Diagnosis and classification of the polycythemias.","volume":"12","author":"Berlin","year":"1975","journal-title":"Semin Hematol"},{"key":"2019111813141526200_B13","first-page":"87","article-title":"The diagnostic criteria of polycythemia rubra vera.","volume":"22","author":"Pearson","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"2019111813141526200_B14","first-page":"177","article-title":"Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group.","volume":"23","author":"Murphy","year":"1986","journal-title":"Semin Hematol"},{"key":"2019111813141526200_B15","article-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues.","author":"Jaffe","year":"2001"},{"key":"2019111813141526200_B16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera.","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"2019111813141526200_B17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.","volume":"348","author":"Palareti","year":"1996","journal-title":"Lancet"},{"key":"2019111813141526200_B18","unstructured":"Cancer Therapy Evaluation Program\n          Common Terminology Criteria for Adverse Events, version 3.0.\n          \n            http:\/\/ctep.cancer.gov\/forms\/CTCAEv3.pdf"},{"key":"2019111813141526200_B19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/asheducation-2006.1.246","article-title":"Myeloproliferative disease in pregnancy and other management issues.","author":"Barbui","year":"2006","journal-title":"Hematology"},{"key":"2019111813141526200_B20","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111813141526200_B21","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"2019111813141526200_B22","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status.","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"2019111813141526200_B23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/09537100310001646969","article-title":"Pathophysiology and treatment of platelet-mediated microvascular disturbance, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.","volume":"15","author":"Michiels","year":"2004","journal-title":"Platelets"},{"key":"2019111813141526200_B24","doi-asserted-by":"crossref","first-page":"338S","DOI":"10.1378\/chest.126.3_suppl.338S","article-title":"Prevention of venous thromboembolism: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy.","volume":"126","author":"Geerts","year":"2004","journal-title":"Chest"},{"key":"2019111813141526200_B25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1245\/s10434-006-9183-9","article-title":"A systematic review of deep vein thrombosis prophylaxis in cancer patients: implications for improving quality.","volume":"14","author":"Leonardi","year":"2007","journal-title":"Ann Surg Oncol. Now available as Ann Surg Oncol"},{"key":"2019111813141526200_B26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2141.2004.05292.x","article-title":"Management of thrombosis in cancer: primary prevention and secondary prophylaxis.","volume":"128","author":"Lee","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111813141526200_B27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/jsre.1997.5233","article-title":"Prospective double arm study of fibrinolysis in surgical patients.","volume":"74","author":"Kosir","year":"1998","journal-title":"J Surg Res"},{"key":"2019111813141526200_B28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1185\/03007998809110450","article-title":"Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent post-operative deep vein thrombosis.","volume":"11","author":"Valle","year":"1988","journal-title":"Curr Med Res Opin"},{"key":"2019111813141526200_B29","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.","volume":"355","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"key":"2019111813141526200_B30","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"2019111813141526200_B31","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 I human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2019111813141526200_B32","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111813141526200_B33","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implication of the JAK2 V617F mutation in essential thrombocythemia.","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"key":"2019111813141526200_B34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK 2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111813141526200_B35","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"2019111813141526200_B36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors and role of leukocytes and JAK2V617F.","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin Thromb Hemost"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/2\/666\/1221183\/zh800208000666.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/2\/666\/1221183\/zh800208000666.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:37:29Z","timestamp":1574084249000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/111\/2\/666\/103764\/Postsurgery-outcomes-in-patients-with-polycythemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,15]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-07-102665","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1112148.568134","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,15]]}}}